Squamous cell carcinoma of the prostate: Long-term survival after combined chemo-radiation

Fernando Munoz, Pierfrancesco Franco, Patrizia Ciammella, Mario Clerico, Mauro Giudici, Andrea Riccardo Filippi, Umberto Ricardi

Research output: Contribution to journalArticle

Abstract

Background: Carcinoma of the prostate gland is the most frequent malignant tumour affecting male population. While the large majority of tumours is represented by adenocarcinoma, pure squamous cell carcinoma comprises only 0,5-1% of all prostate neoplastic lesions. It is characterised by a high degree of malignancy, commonly metastasising to the bone (mainly with osteolytic lesions), liver and lungs with a median survival time of 14 months. Several therapeutic approaches have been employed in the effort to treat prostate pure squamous cell carcinoma, including radical surgery, radiotherapy, chemotherapy and hormonal therapy. All of them mostly failed to gain a significant survival benefit. Case report: We herein report on a case of pure squamous cell carcinoma of the prostate approached with combined-modality treatment, with the administration of 3 courses of cisplatin 75 mg/m2 on day 1 and continous infusion 5-fluorouracil 750 mg/m2 on day 1 to 5 and, subsequently, radiotherapy, with the delivery of a total dose of 46 Gy to the whole pelvis, with additional boost doses of 20 Gy to the prostatic bed and adjunctive 6 Gy to the prostate gland (72 Gy in total). The patient remained free of disease for 5 years, finally experiencing local relapse and, subsequently, dying of acute renal failure due to bilateral uretero-hydro-nephrosis. In addition, we provide a complete overview of all reported cases available within the medical literature. Conclusion: Since it remains questionable which should be the most appropriate therapeutic approach towards prostate pure squamous cell carcinoma, our report demonstrates that a prolonged disease control, with a consistent survival time, may be achieved by the combination of an effective local treatment such as radiotherapy with systemic infusion of chemotherapeutic drugs.

Original languageEnglish
Article number15
JournalRadiation Oncology
Volume2
Issue number1
DOIs
Publication statusPublished - Apr 3 2007

Fingerprint

Prostate
Squamous Cell Carcinoma
Radiation
Survival
Radiotherapy
Nephrosis
Therapeutics
Neoplasms
Pelvis
Acute Kidney Injury
Fluorouracil
Cisplatin
Adenocarcinoma
Carcinoma
Bone and Bones
Recurrence
Drug Therapy
Lung
Liver
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Squamous cell carcinoma of the prostate : Long-term survival after combined chemo-radiation. / Munoz, Fernando; Franco, Pierfrancesco; Ciammella, Patrizia; Clerico, Mario; Giudici, Mauro; Filippi, Andrea Riccardo; Ricardi, Umberto.

In: Radiation Oncology, Vol. 2, No. 1, 15, 03.04.2007.

Research output: Contribution to journalArticle

Munoz, Fernando ; Franco, Pierfrancesco ; Ciammella, Patrizia ; Clerico, Mario ; Giudici, Mauro ; Filippi, Andrea Riccardo ; Ricardi, Umberto. / Squamous cell carcinoma of the prostate : Long-term survival after combined chemo-radiation. In: Radiation Oncology. 2007 ; Vol. 2, No. 1.
@article{8430ffd7e51245e884eec311e0e58b4f,
title = "Squamous cell carcinoma of the prostate: Long-term survival after combined chemo-radiation",
abstract = "Background: Carcinoma of the prostate gland is the most frequent malignant tumour affecting male population. While the large majority of tumours is represented by adenocarcinoma, pure squamous cell carcinoma comprises only 0,5-1{\%} of all prostate neoplastic lesions. It is characterised by a high degree of malignancy, commonly metastasising to the bone (mainly with osteolytic lesions), liver and lungs with a median survival time of 14 months. Several therapeutic approaches have been employed in the effort to treat prostate pure squamous cell carcinoma, including radical surgery, radiotherapy, chemotherapy and hormonal therapy. All of them mostly failed to gain a significant survival benefit. Case report: We herein report on a case of pure squamous cell carcinoma of the prostate approached with combined-modality treatment, with the administration of 3 courses of cisplatin 75 mg/m2 on day 1 and continous infusion 5-fluorouracil 750 mg/m2 on day 1 to 5 and, subsequently, radiotherapy, with the delivery of a total dose of 46 Gy to the whole pelvis, with additional boost doses of 20 Gy to the prostatic bed and adjunctive 6 Gy to the prostate gland (72 Gy in total). The patient remained free of disease for 5 years, finally experiencing local relapse and, subsequently, dying of acute renal failure due to bilateral uretero-hydro-nephrosis. In addition, we provide a complete overview of all reported cases available within the medical literature. Conclusion: Since it remains questionable which should be the most appropriate therapeutic approach towards prostate pure squamous cell carcinoma, our report demonstrates that a prolonged disease control, with a consistent survival time, may be achieved by the combination of an effective local treatment such as radiotherapy with systemic infusion of chemotherapeutic drugs.",
author = "Fernando Munoz and Pierfrancesco Franco and Patrizia Ciammella and Mario Clerico and Mauro Giudici and Filippi, {Andrea Riccardo} and Umberto Ricardi",
year = "2007",
month = "4",
day = "3",
doi = "10.1186/1748-717X-2-15",
language = "English",
volume = "2",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Squamous cell carcinoma of the prostate

T2 - Long-term survival after combined chemo-radiation

AU - Munoz, Fernando

AU - Franco, Pierfrancesco

AU - Ciammella, Patrizia

AU - Clerico, Mario

AU - Giudici, Mauro

AU - Filippi, Andrea Riccardo

AU - Ricardi, Umberto

PY - 2007/4/3

Y1 - 2007/4/3

N2 - Background: Carcinoma of the prostate gland is the most frequent malignant tumour affecting male population. While the large majority of tumours is represented by adenocarcinoma, pure squamous cell carcinoma comprises only 0,5-1% of all prostate neoplastic lesions. It is characterised by a high degree of malignancy, commonly metastasising to the bone (mainly with osteolytic lesions), liver and lungs with a median survival time of 14 months. Several therapeutic approaches have been employed in the effort to treat prostate pure squamous cell carcinoma, including radical surgery, radiotherapy, chemotherapy and hormonal therapy. All of them mostly failed to gain a significant survival benefit. Case report: We herein report on a case of pure squamous cell carcinoma of the prostate approached with combined-modality treatment, with the administration of 3 courses of cisplatin 75 mg/m2 on day 1 and continous infusion 5-fluorouracil 750 mg/m2 on day 1 to 5 and, subsequently, radiotherapy, with the delivery of a total dose of 46 Gy to the whole pelvis, with additional boost doses of 20 Gy to the prostatic bed and adjunctive 6 Gy to the prostate gland (72 Gy in total). The patient remained free of disease for 5 years, finally experiencing local relapse and, subsequently, dying of acute renal failure due to bilateral uretero-hydro-nephrosis. In addition, we provide a complete overview of all reported cases available within the medical literature. Conclusion: Since it remains questionable which should be the most appropriate therapeutic approach towards prostate pure squamous cell carcinoma, our report demonstrates that a prolonged disease control, with a consistent survival time, may be achieved by the combination of an effective local treatment such as radiotherapy with systemic infusion of chemotherapeutic drugs.

AB - Background: Carcinoma of the prostate gland is the most frequent malignant tumour affecting male population. While the large majority of tumours is represented by adenocarcinoma, pure squamous cell carcinoma comprises only 0,5-1% of all prostate neoplastic lesions. It is characterised by a high degree of malignancy, commonly metastasising to the bone (mainly with osteolytic lesions), liver and lungs with a median survival time of 14 months. Several therapeutic approaches have been employed in the effort to treat prostate pure squamous cell carcinoma, including radical surgery, radiotherapy, chemotherapy and hormonal therapy. All of them mostly failed to gain a significant survival benefit. Case report: We herein report on a case of pure squamous cell carcinoma of the prostate approached with combined-modality treatment, with the administration of 3 courses of cisplatin 75 mg/m2 on day 1 and continous infusion 5-fluorouracil 750 mg/m2 on day 1 to 5 and, subsequently, radiotherapy, with the delivery of a total dose of 46 Gy to the whole pelvis, with additional boost doses of 20 Gy to the prostatic bed and adjunctive 6 Gy to the prostate gland (72 Gy in total). The patient remained free of disease for 5 years, finally experiencing local relapse and, subsequently, dying of acute renal failure due to bilateral uretero-hydro-nephrosis. In addition, we provide a complete overview of all reported cases available within the medical literature. Conclusion: Since it remains questionable which should be the most appropriate therapeutic approach towards prostate pure squamous cell carcinoma, our report demonstrates that a prolonged disease control, with a consistent survival time, may be achieved by the combination of an effective local treatment such as radiotherapy with systemic infusion of chemotherapeutic drugs.

UR - http://www.scopus.com/inward/record.url?scp=34248383936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248383936&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-2-15

DO - 10.1186/1748-717X-2-15

M3 - Article

C2 - 17407588

AN - SCOPUS:34248383936

VL - 2

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 15

ER -